Here's the Biggest Challenge Pfizer Faces Right Now

Here's the Biggest Challenge Pfizer Faces Right Now

It's fair to say Pfizer (NYSE: PFE) has become a coronavirus vaccine powerhouse. The big pharma company landed the first Emergency Use Authorization (EUA) for a COVID-19 vaccine in December. Pfizer and partner BioNTech expect the vaccine to generate about $15 billion in revenue this year.